NYSE:AVTR
Avantor, Inc.
A global mission-critical supplier to life sciences and healthcare industries facing recent profitability headwinds.
Key Metrics
Investment Thesis
Bull Case
Despite recent losses, Avantor maintains a robust balance sheet with over $2.45 billion in current assets and significant cash reserves that can fund operations during market volatility. The company's dominant market position in mission-critical life sciences supply chains offers strong long-term growth potential as the global pharmaceutical and biotech sectors expand. Strategic debt restructuring through $1.11 billion in issuances suggests management is actively optimizing capital structure to restore profitability.
Bear Case
The sharp decline in net income from positive figures in 2022-2024 to a $530.2 million loss raises serious concerns about margin compression and pricing power issues. High leverage with $3.92 billion in long-term debt limits financial flexibility, especially if interest rates remain elevated or credit ratings are downgraded. Working capital dynamics appear strained with inventory increases of $109.4 million not fully offset by receivable growth, potentially signaling demand weakness or obsolescence risks.
About Avantor, Inc.
Avantor, Inc. (NYSE: AVTR) is a leading global provider of mission-critical products, services, and solutions to life sciences and healthcare customers. Operating primarily in the US and Europe, the company serves pharmaceutical manufacturers, medical device makers, and academic research institutions by supplying high-purity chemicals, laboratory consumables, and specialized equipment. With total assets exceeding $11.7 billion and revenue of $6.55 billion, Avantor supports essential supply chains across biotechnology, healthcare, and education sectors.
Analysis
Management Discussion
Recent financial performance shows a sharp deterioration with revenue declining from $7.51 billion in 2022 to $6.55 billion in the most recent year reported. Net income swung from $711.5 million in 2024 to a significant loss of $530.2 million, while operating expenses rose to $2.39 billion against gross profit of only $2.14 billion. Cash position remains healthy at $368.3 million but the company repaid $1.43 billion in debt while issuing just $1.11 billion, indicating aggressive deleveraging amid earnings pressure.
Industry Overview
The global life sciences supply chain industry is characterized by high barriers to entry due to stringent regulatory requirements and the need for specialized technical expertise in handling hazardous materials. Market consolidation continues as companies seek economies of scale to serve increasingly complex pharmaceutical manufacturing processes and personalized medicine demands. Industry leaders compete on service reliability, technical support, and comprehensive portfolio breadth rather than price alone.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $7.51B | $6.97B | $6.78B | $6.55B |
| Cost of Revenue | $4.91B | $4.60B | $4.50B | $4.41B |
| Gross Profit | $2.60B | $2.36B | $2.28B | $2.14B |
| Operating Expenses | $1.47B | $1.67B | $1.19B | $2.39B |
| Operating Income | $1.13B | $696.4M | $1.08B | $-246.2M |
| G&A | $1.47B | $1.51B | $1.64B | $1.60B |
| Stock-Based Comp | $45.8M | $40.5M | $46.8M | $46.4M |
| D&A | $405.5M | $402.3M | $405.5M | $410.2M |
| Depreciation | $87.2M | $94.6M | $105.7M | $109.1M |
| Amortization | $318.3M | $307.7M | $299.8M | $301.1M |
| Other OpEx | $0 | $160.8M | $-446.6M | $790.1M |
| Non-Operating Income | $-279.1M | $-285.9M | $-230.9M | $-195.1M |
| Interest Expense | $265.8M | $284.8M | — | — |
| Pre-Tax Income | $851.1M | $410.5M | $853.9M | $-441.3M |
| Income Tax | $164.6M | $89.4M | $142.4M | $88.9M |
| Continuing Ops | $686.5M | $321.1M | $711.5M | $-530.2M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $686.5M | $321.1M | $711.5M | $-530.2M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $686.5M | $321.1M | $711.5M | $-530.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $2.66B | $2.38B | $2.15B | $2.45B |
| Cash & Equivalents | $372.9M | $262.9M | $261.9M | $365.4M |
| Accounts Receivable | $1.22B | $1.15B | $1.03B | $1.07B |
| Inventory | $913.5M | $828.1M | $731.5M | $818.2M |
| Other Current Assets | $153.1M | $143.7M | $118.7M | $193.0M |
| Long-Term Assets | $10.81B | $10.59B | $9.97B | $9.34B |
| PP&E (Net) | $727.0M | $737.5M | $708.1M | $766.8M |
| Goodwill | $5.65B | $5.72B | $5.54B | $4.99B |
| Operating Leases | $118.7M | $120.7M | $156.5M | $164.5M |
| Other LT Assets | $4.31B | $4.01B | $3.56B | $3.43B |
| Total Assets | $13.46B | $12.97B | $12.11B | $11.79B |
| Current Liabilities | $1.66B | $1.48B | $2.01B | $1.38B |
| Accounts Payable | $758.2M | $625.9M | $662.8M | $741.7M |
| Current Debt | $364.2M | $259.9M | $821.1M | $30.8M |
| Current Leases | $35.6M | $36.2M | $29.8M | $33.5M |
| Other Current Liab | $500.8M | $558.3M | $493.8M | $572.9M |
| Long-Term Liabilities | $6.95B | $6.24B | $4.15B | $4.85B |
| Long-Term Debt | $5.92B | $5.28B | $3.23B | $3.92B |
| LT Operating Leases | $86.6M | $88.5M | $143.2M | $152.0M |
| Other LT Liab | $940.2M | $874.6M | $772.4M | $783.3M |
| Total Liabilities | $8.61B | $7.72B | $6.16B | $6.23B |
| Shareholders' Equity | $4.86B | $5.25B | $5.96B | $5.57B |
| Paid-In Capital | $3.79B | $3.83B | $3.94B | $3.98B |
| Retained Earnings | $1.17B | $1.49B | $2.20B | $1.67B |
| AOCI | $-100.3M | $-69.0M | $-184.0M | $-16.9M |
| Total L&E | $13.46B | $12.97B | $12.11B | $11.79B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $686.5M | $321.1M | $711.5M | $-530.2M |
| Non-Cash Adjustments | $-195.6M | $844.1M | $61.0M | $872.9M |
| Working Capital Changes | $352.7M | $-295.2M | $68.3M | $281.1M |
| Cash from Operations | $843.6M | $870.0M | $840.8M | $623.8M |
| Capital Expenditures | $133.4M | $146.4M | $148.8M | $128.8M |
| Cash from Investing | $-109.6M | $-143.7M | $438.9M | $-130.5M |
| Debt Issuances | $327.2M | $0 | $0 | $1.11B |
| Debt Repayments | $947.0M | $846.0M | $1.34B | $1.43B |
| Share Buybacks | — | — | — | $75.1M |
| Cash from Financing | $-648.7M | $-843.7M | $-1.28B | $-409.4M |
| FX Effect | $-15.5M | $8.2M | $-21.5M | $19.7M |
| Net Change in Cash | $69.8M | $-109.2M | $-23.0M | $103.6M |
| Beginning Cash | $327.1M | $396.9M | $287.7M | $264.7M |
| Ending Cash | $396.9M | $287.7M | $264.7M | $368.3M |
Frequently Asked Questions
How does Avantor, Inc. make money?
The company's revenue is driven by its core segments including Life Sciences (pharmaceuticals and medical devices), Healthcare (hospitals and ambulatory surgery centers), and Education/Research (academic institutions and government labs). Financially, the firm manages significant inventory levels of $818.2 million and substantial accounts receivable of $1.07 billion to support its broad product distribution network.
What are the main risks for AVTR?
Significant profitability erosion is evident with a net loss of $530.2 million in the latest period, contrasting sharply with prior years' earnings. The company carries substantial debt obligations including $3.92 billion in long-term debt and $4.85 billion in total liabilities against only $5.57 billion in equity. Operational efficiency challenges are highlighted by a negative cash flow from operations to net income ratio of -1.16, suggesting potential accounting or working capital timing issues.
What is AVTR's competitive advantage?
Avantor leverages a massive global footprint and deep technical expertise to secure long-term contracts with major pharmaceutical and biotech firms, creating high switching costs for customers. The company's diversified revenue streams across multiple verticals provide resilience against single-sector downturns, while its extensive supply chain logistics capabilities ensure reliable delivery of mission-critical materials.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.